Huntington’s Disease: New Frontiers in Therapeutics
- 14 February 2021
- journal article
- review article
- Published by Springer Science and Business Media LLC in Current Neurology and Neuroscience Reports
- Vol. 21 (3), 1-9
- https://doi.org/10.1007/s11910-021-01093-3
Abstract
Purpose of Review This article describes and discusses new potential disease-modifying therapies for Huntington’s disease that are currently in human clinical trials as well as promising new therapies in preclinical development. Recent Findings Multiple potential disease-modifying therapeutics for HD are in active development, including direct DNA/gene therapies, RNA modulation, and therapies targeted at aberrant downstream pathways. Summary The etiology of Huntington’s disease (HD) is well-known as an abnormally expanded trinucleotide repeat within the huntingtin gene. However, the pathogenesis downstream of the mutant huntingtin gene is complex, involving multiple toxic pathways, including abnormal protein fragmentation and neuroinflammation. The current treatment of HD focuses largely on symptomatic management. This article discusses new, potential disease-modifying therapies that are currently in human clinical trials and preclinical development.Keywords
This publication has 74 references indexed in Scilit:
- Synthetic zinc finger repressors reduce mutant huntingtin expression in the brain of R6/2 miceProceedings of the National Academy of Sciences of the United States of America, 2012
- Spt4 Is Selectively Required for Transcription of Extended Trinucleotide RepeatsCell, 2012
- Bifunctional Anti-Huntingtin Proteasome-Directed Intrabodies Mediate Efficient Degradation of Mutant Huntingtin Exon 1 Protein FragmentsPLOS ONE, 2011
- Preclinical Safety of RNAi-Mediated HTT Suppression in the Rhesus Macaque as a Potential Therapy for Huntington's DiseaseMolecular Therapy, 2011
- Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trialThe Lancet Neurology, 2011
- Zinc-finger directed double-strand breaks within CAG repeat tracts promote repeat instability in human cellsProceedings of the National Academy of Sciences of the United States of America, 2009
- Nonallele-specific Silencing of Mutant and Wild-type Huntingtin Demonstrates Therapeutic Efficacy in Huntington's Disease MiceMolecular Therapy, 2009
- A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's diseaseThe Journal of Experimental Medicine, 2008
- Differential loss of striatal projection systems in Huntington’s disease: a quantitative immunohistochemical studyJournal of Chemical Neuroanatomy, 2004
- Aggregation of Huntingtin in Neuronal Intranuclear Inclusions and Dystrophic Neurites in BrainScience, 1997